Covetrus, Inc. (NASDAQ:CVET) Insider Dustin Finer Sells 1,500 Shares

Covetrus, Inc. (NASDAQ:CVET) insider Dustin Finer sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, June 8th. The shares were sold at an average price of $27.86, for a total value of $41,790.00. Following the transaction, the insider now owns 36,710 shares in the company, valued at $1,022,740.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Dustin Finer also recently made the following trade(s):

  • On Wednesday, June 2nd, Dustin Finer sold 2,322 shares of Covetrus stock. The shares were sold at an average price of $27.28, for a total value of $63,344.16.
  • On Tuesday, May 4th, Dustin Finer sold 1,500 shares of Covetrus stock. The shares were sold at an average price of $30.43, for a total value of $45,645.00.
  • On Tuesday, April 6th, Dustin Finer sold 1,500 shares of Covetrus stock. The shares were sold at an average price of $29.38, for a total value of $44,070.00.

Shares of Covetrus stock traded up $0.36 during trading on Thursday, reaching $27.83. The company’s stock had a trading volume of 285,178 shares, compared to its average volume of 754,568. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.27 and a current ratio of 2.09. The stock has a fifty day moving average price of $28.23. The company has a market cap of $3.80 billion, a price-to-earnings ratio of -349.58, a price-to-earnings-growth ratio of 1.74 and a beta of 2.05. Covetrus, Inc. has a one year low of $15.03 and a one year high of $40.78.

Several institutional investors have recently bought and sold shares of CVET. Clayton Dubilier & Rice LLC increased its stake in shares of Covetrus by 32.4% in the fourth quarter. Clayton Dubilier & Rice LLC now owns 33,676,829 shares of the company’s stock worth $967,872,000 after purchasing an additional 8,246,585 shares during the period. Morgan Stanley increased its stake in shares of Covetrus by 18.5% in the fourth quarter. Morgan Stanley now owns 10,998,767 shares of the company’s stock worth $316,105,000 after purchasing an additional 1,714,264 shares during the period. BlackRock Inc. grew its position in Covetrus by 9.5% during the fourth quarter. BlackRock Inc. now owns 15,921,045 shares of the company’s stock worth $457,572,000 after buying an additional 1,384,744 shares in the last quarter. Norges Bank acquired a new stake in Covetrus during the fourth quarter worth about $38,003,000. Finally, JPMorgan Chase & Co. grew its position in Covetrus by 29.6% during the fourth quarter. JPMorgan Chase & Co. now owns 3,302,918 shares of the company’s stock worth $94,927,000 after buying an additional 754,020 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Several equities analysts have weighed in on CVET shares. Raymond James raised their target price on Covetrus from $31.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, March 2nd. Zacks Investment Research upgraded Covetrus from a “sell” rating to a “hold” rating in a report on Thursday, May 20th. Finally, Barclays assumed coverage on Covetrus in a report on Wednesday, February 17th. They set an “overweight” rating and a $48.00 target price on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Covetrus has an average rating of “Buy” and a consensus target price of $33.40.

About Covetrus

Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Insider Buying and Selling by Quarter for Covetrus (NASDAQ:CVET)

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.